Back
Return
Biography
Dr. James Leslie Karagianis

Dr. James Leslie Karagianis

USMD Zyprexa/Symbyax, Eli Lilly and Company

USA


Email: karagianis_jamie@lilly.com


Qualifications

1985 M.D., Medical: Memorial University of Newfoundland (MUN)

1983 B.S., Medical: Memorial University of Newfoundland (MUN)


Publications (Selected)

  1. A Holy Condition. Diagnosis, 1987;4(1):125.
  2. A Case of Tourette Syndrome Developing During Haloperidol Treatment. Canadian Journal of Psychiatry, 1990;35(3):228-232.
  3. Frequency of Electroconvulsive Therapy Use at a Provincial Mental Hospital: A Retrospective Study. Canadian Journal Of Psychiatry 1994;39:551-562.
  4. Clozapine - Associated Neuroleptic Malignant Syndrome: Two new cases and review of the literature. Annals of Pharmacotherapy 1999;33:623-30.
  5. Rapid Tranquilization With Olanzapine in Acute Psychosis: A Case Series. J Clin Psychiatry 2001;62(suppl 2):12-16.
  6. High Dose Olanzapine and Prolactin Levels. Karagianis J, Baksh A. Journal of Clinical Psychiatry 2003, 64(10):1192-1194.
  7. Switching Treatment-Resistant Patients with Schizophrenia or Schizoaffective Disorder to Olanzapine: a one-year open label study with five–year follow-up. Karagianis J, LeDrew K, Walker D. Current Medical Research and Opinion 2003, 19(6):473-480.
  8. Case Report: Edema Related to Olanzapine Therapy. Deshauer D, Erwin L, Karagianis J. Canadian Family Physician 2006;52:620-621.
  9. Is Hunger a Driver of the Cognitive Development? Treuer T, Karagianis J. Neuropsychopharmacology 2006;31(10):2326-7.
  10. What Do We Know About Insulin Resistance and Glucose Metabolism in Patients with Schizophrenia Treated with Antipsychotics? Karagianis J, Poole-Hoffman V, Stauffer V, Treuer T. J Clin Psychiatry. 2007 May;68(5):799-800.
  11. Reviewing CATIE for Clinicians: Balancing Benefits and Risks Using Evidence Based Medicine Tools. Karagianis J, Rosenbluth R, Tohen M, Ascher-Svanum H, Treuer T, Silva de Lima M, Citrome L. Current Medical Research and Opinion 2007, 23(10):2551-7.
  12. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics Citrome L, Holt RIG, Zachry WM, Clewell JD, Orth PA, Karagianis J, Hoffmann VP. Annals of Pharmacotherapy, 2007, 41(10): 1593-1603.
  13. Parasitosis, Dopaminergic Modulation and Metabolic Disturbances in Schizophrenia: Evolution of a Hypothesis. Treuer T, Martenyi F, Karagianis J. Neuro Endocrinol Lett. 2007, Oct;28(5):535-40.
  14. Can Increased Food Intake Improve Psychosis? A Brief Review and Hypothesis. Treuer T, Karagianis J, Hoffmann VP. Invited Review for Current Molecular Pharmacology. 2008, 1(3):270-272.
  15. Orally Disintegrating Psychotropics and Possible Impact on Weight. Karagianis J, Poole-Hoffmann V, Arranz B, Treuer T, Maguire GA, de Haan L, Chawla B. Hum Psychopharmacol. 2008 Jun;23(4):275-81.
  16. Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. Stauffer V, Karagianis J, Sutton V, AscherSvanum H, Treuer T, Silva de Lima M, Ball T, Poole-Hoffmann V, Tohen M. Clinical Schizophrenia and Related Psychoses, 2008 July:136-146.
  17. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: Comparison of real-life effectiveness in the treatment of agitation. Castle DJ, Udristoiu T, Yoon Kim C, Sarosi A, Pidrman V, Omar AN, Rosales JI, Melamed Y, Isik T, Karagianis J, Treuer T. World J Biol Psychiatry. 2009 Jan 9:43-53.
  18. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS Study. Karagianis J, Grossman L, Landry J, Reed V, de Haan L, Maguire GA, Hoffmann VP, Milev R. Schizophrenia Research 2009;113:41-48.
  19. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania. Chandrasena R, Dvořáková D, Lee SI, Loza N, Mosolov SN, Osváth P, Pregelj P, Walton RJ, Karagianis J, Treuer T. Int J Clin Pract. 2009 Aug;63(8):1249-58. Epub 2009 Jun 24.
  20. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Karagianis J, Williams R, Davis L, Hanley JB, Chandrasena R, Thakur A and Dickson R. Current Medical Research and Opinion 2009; 25 (9):2121-32.
  21. Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Karagianis J, Novick D, Haro JM, Dossenbach M, Montgomery W, Pecenak J, Treuer T, Walton R, Lowry A. International Journal of Clinical Practice 2009;63(11):1578-88.
  22. Changes in Weight and Metabolic Parameters during treatment with Antipsychotics and Metformin. Do the data inform as potential guideline development? A systematic review of clinical studies. Bushe C, Bradley A, Doshi S, Karagianis J. Int J. Clin. Pract. 2009 Dec;63(12):1743-61. Epub 2009 Oct 19.
  23. Pharmacological treatment outcomes in Latin American patients with bipolar I disorder. Garcia-Bonetto G, Nieto I, Chapa R, Adrianzén C, Brnabic A, Meyers A, Granger R, Dossenbach M, Karagianis J, Ruiz I. Archivos de Neurociencias Vol. 14 no. 4 octubre_diciembre 2009.
  24. Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder. Tohen M, Sniadecki J, Sutton VK, Degenhardt EK, Karagianis JL, Sagman D, Jacobson JG. Journal of Clinical Psychopharmacology 2009 Dec;29(6):520-8.
  25. The Number Needed to Treat for All-Cause Medication Discontinuation in the Treatment of Schizophrenia: Consistency Across World Geographies and Study Designs. D. Novick, H. Ascher-Svanum, B. Zhu, A. Brnabic, V. Stauffer, X. Peng, J. Karagianis, E. Perrin. Pharmacopsychiatry 2010 May;43(3):81-5. Epub 2009 Dec 16.